论文部分内容阅读
冠状动脉内溶栓疗法(简称PTCR)是治疗急性心肌梗塞(AMI)一种新方法。以往对AMI的治疗是针对其早期的并发症,新疗法的目的则是恢复冠状动脉血流,缩小梗塞范围和保护左室功能。美国和西欧多采用冠状动脉内链激酶疗法(IC-SK),日本则采用冠状动脉内尿激酶疗法(IC-UK)。链激酶和尿激酶是纤溶酶原激活剂,能将内源性纤溶酶原激活成纤溶酶,它们属第一代溶拴制剂,现将PTCR的病例选择、临床效果、并发症等有关问题介绍如下。适应证PTCR的适应证为进展期心肌梗
Intra-coronary thrombolysis (PTCR) is a new approach to the treatment of acute myocardial infarction (AMI). In the past, the treatment of AMI was aimed at its early complications. The new therapy aimed to restore coronary blood flow, reduce infarct size and protect left ventricular function. Coronary artery streptokinase therapy (IC-SK) is mostly used in the United States and Western Europe, while intracoronary urokinase therapy (IC-UK) is used in Japan. Streptokinase and urokinase are plasminogen activators, can endogenous plasminogen activation into plasmin, which is the first generation of soluble tethered preparations, now PTCR case selection, clinical effects, complications, etc. The questions are as follows. Indications PTCR indications for advanced myocardial infarction